News Content
**Phase 1: The 1-3 day "activation and awakening period"** is the initial manifestation of its effect. When the drug first acts on the pituitary gland, it briefly stimulates a large secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a transient increase in sex hormones (testosterone, estrogen). The effects of this phase vary in different scenarios: prostate cancer patients may temporarily experience increased bone pain, and endometriosis patients may experience a short-term increase in dysmenorrhea; in assisted reproduction, this phase can induce early follicular development, laying the foundation for subsequent ovulation induction.https://www.fiercerawsource.com/peptides/premium-high-purity-peptides-triptorelin-gnrh.html
**The second stage: the 2-4 week "suppression and stabilization period"** is crucial for treatment effectiveness. Continuous medication desensitizes the pituitary gland, significantly suppressing LH and FSH secretion, and gradually lowering sex hormone levels to therapeutic targets: in prostate cancer patients, testosterone levels can drop to castration levels (<50 ng/dL), and in endometriosis patients, estrogen levels can drop to postmenopausal levels, thus alleviating pain; in assisted reproduction, it achieves precise suppression of ovulation, preventing premature follicle maturation.
Individual differences may slightly adjust the onset time: those with good liver and kidney function have stable metabolism and a more regular onset; high initial doses can shorten the suppression period to 10-14 days.
Endocrinologists emphasize: "Hormonal fluctuations during the initial stimulation phase require vigilance; risk assessment is necessary through hormone level monitoring. Its 'initially high, then low' onset characteristic means that 2-4 weeks after medication is the critical point for efficacy evaluation."
